Article (Scientific journals)
L’étude du mois. Traitement de l’hépatocarcinome au stade palliatif par Sorafenib (Nexavar) :Résultats de l’étude SHARP (Sorafenib Hepatocarcinoma Assessment Randomized Protocol)
Detry, Olivier; Delwaide, Jean; Deroover, Arnaud et al.
2009In Revue Médicale de Liège, 64 (3), p. 168-170
Peer reviewed
 

Files


Full Text
Sorafenib.2009.RMDLg.HCC.pdf
Publisher postprint (324.98 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Liver transplantation; cancer; oncology; hepatectomy; radiofrequency ablation
Abstract :
[en] Curative management of early-stage hepatocarcinoma may include partial hepatic resection, liver transplantation or tumoral necrosis using radiofrequency ablation or alcoholisation. Until recently, no efficient therapeutic mean was available for advanced hepatocarcinoma. Sorafenib is a multikinase inhibitor that decreases tumoral proliferation and angiogenesis, and increases apoptosis in many cancer models. The results of a phase 3 randomized, multicentric, study, entitled SHARP, have now demonstrated that Sorafenib increases survival in patients with advanced hepatocarcinoma developed in Child A cirrhosis. Mean survival gain was a little less than 3 months, without any radiologic response or improvement in the delay before symptomatic progression of the disease. The monthly cost of Sorafenib is a little more than 5,000 euros. It is now crucial to evaluate the potential role of Sorafenib in adjuvant therapy after liver resection or radiofrequency ablation of hepatocarcinoma. The CHU of Liège is taking part to a randomized, multicentric study evaluating the use of Sorafenib after liver resection or radiofrequency ablation for hepatocarcinoma. Another future evaluation could be the association of Sorafenib with other antitumoral agents.
Disciplines :
Gastroenterology & hepatology
Oncology
Surgery
Author, co-author :
Detry, Olivier  ;  Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation
Delwaide, Jean ;  Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie
Deroover, Arnaud ;  Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation
Meunier, Paul ;  Centre Hospitalier Universitaire de Liège - CHU > Imagerie médicale
Lamproye, Anne ;  Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie
Honore, Pierre ;  Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation
Polus, Marc ;  Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie
Language :
French
Title :
L’étude du mois. Traitement de l’hépatocarcinome au stade palliatif par Sorafenib (Nexavar) :Résultats de l’étude SHARP (Sorafenib Hepatocarcinoma Assessment Randomized Protocol)
Alternative titles :
[en] Study of the Month. Palliative management of hepatocarcinoma with Sorafenib (Nexavar) : Results of the SHARP (Sorafenib Hepatocarcinoma Assessment Randomized Protocol) trial
Publication date :
March 2009
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Hopital de Baviere, Liège, Belgium
Volume :
64
Issue :
3
Pages :
168-170
Peer reviewed :
Peer reviewed
Available on ORBi :
since 26 November 2008

Statistics


Number of views
537 (39 by ULiège)
Number of downloads
432 (5 by ULiège)

Scopus citations®
 
7
Scopus citations®
without self-citations
5

Bibliography


Similar publications



Contact ORBi